Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Urinary Bladder Neoplasms 3Urothelial Carcinoma of the Bladder 1Squamous Cell Carcinoma of Head and Neck 1Non-Muscle Invasive Bladder Urothelial Carcinoma 1Non-Muscle Invasive Bladder Neoplasms 1Neuroblastoma 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Laryngeal Neoplasms 1Ganglioneuroblastoma 1Carcinoma 1Brain Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 9Specimen Handling 8Cisplatin 5Cetuximab 5Platinum 41,2-diaminocyclohexaneplatinum II citrate 4cemiplimab 3Radiotherapy 3Immunoglobulin G 3Disulfides 3Biopsy 3(225)Ac-DOTA-c(RGDyK) 3pembrolizumab 2Radiotherapy, Intensity-Modulated 2Radiation 2Nivolumab 2Carboplatin 2Bevacizumab 2trastuzumab deruxtecan 1temsirolimus 1niraparib 1ipatasertib 1durvalumab 1dostarlimab 1cabozantinib 1atezolizumab 1Valproic Acid 1Ultrasonography 1Transurethral Resection of Bladder 1Tramadol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mouth Neoplasms × Transurethral Resection of Bladder × 30 days × Clear all
NCT06980038 2026-06-01

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
44 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Laryngeal Neoplasms, Mouth Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡